Meeting
2014 Gastrointestinal Cancers Symposium
Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO).
Authors
Renata D'Alpino Peixoto
BC Cancer Agency, Vancouver, BC, Canada
Renata D'Alpino Peixoto , Daniel John Renouf , Howard John Lim , Winson Y. Cheung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 259)
DOI
10.1200/jco.2014.32.3_suppl.259
Abstract #
259
Poster Bd #
B32
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2017 Gastrointestinal Cancers Symposium
Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study.
First Author: Hannah Marie Cherniawsky
Poster
2015 ASCO Annual Meeting
Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.
First Author: Alix Portal
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma.
First Author: Andrea Pretta